Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Goodwill & Intangibles (2023 - 2025)

Telix Pharmaceuticals (TLX) posted Goodwill & Intangibles of $791.8 million for Q4 2025, up 190.96% on a QoQ basis from $272.1 million in Q4 2024, and up 190.96% year-over-year from $272.1 million in Q4 2024.

Telix Pharmaceuticals (TLX) has 3 years of Goodwill & Intangibles data on file, last reported at $791.8 million in Q4 2025.

  • In Q4 2025, Goodwill & Intangibles rose 190.96% year-over-year to $791.8 million; the TTM figure through Dec 2025 stood at $791.8 million (up 190.96% YoY), while the FY2025 annual figure was $791.8 million, up 190.96% from the prior year.
  • Goodwill & Intangibles climbed to $791.8 million in Q4 2025, from $272.1 million in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $791.8 million in Q4 2025 and bottomed at $71.4 million in Q4 2023.
  • A 3-year average of $378.4 million and a median of $272.1 million in 2024 frame the typical range for Goodwill & Intangibles.
  • Annual changes were most pronounced in 2024 — Goodwill & Intangibles jumped 281.2% — and 2025, when it soared 190.96%.
  • Year by year, Goodwill & Intangibles stood at $71.4 million in 2023, then jumped by 281.2% to $272.1 million in 2024, then jumped by 190.96% to $791.8 million in 2025.
  • The last three Goodwill & Intangibles figures came in at $791.8 million (Q4 2025), $272.1 million (Q4 2024), and $71.4 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Telix Pharmaceuticals 4.52 Bn 4.38 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 791.81 Mn
Dec 31, 2024 272.13 Mn
Dec 31, 2023 71.39 Mn